Background: Sorafenib has limited survival benefits with lower tumor response rates in hepatocellular carcinoma (HCC). Many researchers have attempted to identify predictors for sorafenib. We compared the role of lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), platelet/neutrophil ratio (PNR), systemic inflammation response index (SIRI) and systemic immune inflammation (SII) in patients with HCC received sorafenib treatment in this study.
Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver.
Although surveillance programs are used more frequently, the majority of HCC patients are diagnosed at an advanced stage (1) . In addition, some patients with early-to-moderate HCC progress to advanced stage disease during follow-up. Only palliative treatment options are available for this group of patients.
Sorafenib is a tyrosine kinase inhibitor with effects on tumor angiogenesis and proliferation, and two placebo-controlled randomized trials have shown that this drug prolongs survival in advanced HCC patients (2, 3) . However, due to the primary and acquired drug resistance mechanisms developed when taking sorafenib treatment, the drug has limited survival benefits with lower tumor response rates than expected (4) . Many researchers have attempted to identify baseline or pretreatment predictors for sorafenib. Because the same effect was not seen in all HCC patients and response rates were not satisfactory (2) . Recently, systemic inflammation was reported to be closely related to malignancy (5) . Inflammation plays a significant role in the development and progression of tumor. Immune and inflammatory cells, such as neutrophils, monocytes and lymphocytes in the systemic circulation, may contribute to tumor cell invasion and metastasis (6) . Different inflammation-based scores have been proposed and are considered useful in this respect (7) .
We compared the role of lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), platelet/neutrophil ratio (PNR), systemic inflammation response index (SIRI) and systemic immune inflammation (SII) in patients with HCC received sorafenib treatment in this study.
Materials and Methods

Study Populations ve Design
We retrospectively recorded the patients who were followed up with the diagnosis of HCC at Gaziantep University School of Medicine between January 2011 and December 2018. The number of patients who were prescribed sorafenib treatment was 98. However, 80 patients who had used sorafenib treatment for at least 4 weeks were analyzed. This study was This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. 
Results
Patient Characteristics
The mean age was 69 (range 29-83) years and 83.8 % were male gender. Etiology of HCC were infection of heatitis B (n=49, 61%), infection of hepatitis C (n=8, 10%), non-alcoholic fatty liver disease (n=10, 12.5%), alcoholic liver disease (n=4, 5%) and cryptogenic (n=9, 11.25%). 15 % of patients had extra-hepatic metastases.
Median follow up time was 31.5 weeks (range 5-155 weeks). There were 72 (90%) deaths in total. At time of analysis, 8 (10%) patients were actively receiving sorafenib. A summary of the distribution of clinical variables was outlined in Table 1 .
In our study, OS of patients according to HCC diagnosis was 34 weeks (95% CI:29.22-38.77); OS based on the use of sorafenib treatment was 29 weeks (95% CI 20.41-37.58); the PFS value was 16 weeks (95% CI:12.04-19.95).
LMR, NMR, PNR, SIRI, SII and clinical outcome
Median PFS and OS, according to LMR, NMR, PNR, SIRI and SII, were shown in table 2, figure 1 and figure 2.
The cut-off point of LMR was determined by the ROC analysis. The cut-off point was 1.4 for LMR (p= 0.737; AUC=0.535; sensitivity= 29.17% (95% CI:19.0-41.1); specifity=100.0% (95% CI:63.1-100.0)). The PFS value for both LMR ≤ 1.4 and > 1.4 was 16 weeks and there was no statistically significant difference (p= 0.601). Median OS were 31 weeks (95% CI:24.61-37.38) for LMR >1.4 and 18 weeks (95% CI:20.41-37.58) for LMR ≤1.4 (p= 0.155).
The cut-off point for NMR was 5.2 (p = 0.005; AUC= 0.805; sensitivity= 81.94% (95% CI:71.1-90); specifity= 87.5% (95% CI:47.3-99.7)). Median Table 3) .
Discussion
Although HCC is important among cancer-related deaths, few markers have been identified for predicting of survival. Therefore, it is very significant to find inexpensive, appropriate and reliable markers to predict prognosis in HCC patients. As a prognostic marker in cancer patients in worldwide, interest for systemic inflammation is increasing. In our study, only low SIRI value was found to be associated with increased survival in patients receiving sorafenib with HCC. positive effect on the immune-related response to the tumor. In a meta-analysis, it was shown that LMR had a good prognostic effect (8) . In our study, there was no statistically significant difference for PFS and OS with values of 1.4 for LMR. However, when the LMR ≤1.4 and >1.4 group were compared, a positive 13 week difference in OS value was observed in favor of 1.4.
Neutrophil is the most common cell among the white blood cells and has the shortest half-life.
It is the first cell to respond to trauma or attack. Therefore, it is involved in the formation of immune response by contacting the tumor cells in the first order (9) . In previous studies, NMR were examined in breast and prostate cancer patients in addition to other inflammationrelated parameters in cancer (10, 11) . To the best of our knowledge of literature, NMR was investigated first time with HCC in our study. The cut-off value was 5.2 and there was a numerical difference in PFS and OS values in favor of <5.2, but there was no statistically significant difference. In the light of previous studies, low levels of neutrophil and monocyte were known as good parameters. Neutrophil secretes vascular endothelial growth factor (VEGF) and proteases such as matrix metalloproteinase and elastase enzymes, causing cancer cells to invade and metastasize. Monocytes also increase cancer cell migration and inhibit immunity to the tumor cell (12) . Although there was no statistically significant difference in our study, it was thought that the high level of monocyte value might be important for the response to the tumor.
As seen in NMR, low levels of neutrophils in PNR cause better results in response to tumor.
Platelet-derived growth factor and VEGF, which are act as main factors on cell proliferation, angiogenesis and tumor metastasis, are secreted from platelets (13) . These cells contain proinflammatory molecules and cytokines, therefore they are involved in inflammatory and immune responses (14) . In our study, when compared to PNR ≤ 44.8 to > 44.8, OS benefit was observed in favor of > 44.8 (33 versus 20 weeks, p= 0.055).
SIRI is an another simple, noninvasive prognostic marker and more comprehensive than other markers. In the study of Xu et al, the relationship between survival and HCC was investigated (6) . According to this study, median OS was longer with low SIRI in patients receiving local www.erciyesmedj.com treatment or sorafenib treatment. In our study, we have shown that there was a relation with a low SIRI value (< 2.2) and OS in the unresectable or metastatic patients (18 versus 38 weeks, p=0.005). There was also a difference between a low value of SIRI (< 2.2) and PFS, but not statistically significant (12 versus 20 weeks, p= 0.098).
SII is another comprehensive marker. Gardini et al reported a prognostic effect in 56 HCC patients receiving sorafenib treatment (15) . It had been shown that high SII values had a negative effect on survival. In our study, PFS (13 versus 20 weeks) and OS (20 versus 31 weeks) values were found to be decreased in patients with cut off value ≥523, but there was no statistically difference (p= 0.086, p= 0.209, respectively).
In our study, we have shown that LMR, SIRI and SII values have a prognostic effect in accordance with the literature. NMR and PNR values were first studied in patients with HCC in our study. According to the results of these two markers, we have shown that the low neutrophil value is more effective on prognosis than low monocyte and platelet values.
Although the parameters calculated using two parameters were more practical, as shown in SIRI and SII, the results may be more effective with the use of more parameters. We found numerical differences between the groups but, statistically significant difference wasn't observed.
In recent years, great improvement has been made in immunotherapies for all of the cancer types. There is a need for biomarkers to predict the clinical efficacy of immune check point inhibitors. In patients with lung cancer receiving immunotherapy, high neutrophil/lymhocyte ratio has been shown to be associated with poor prognosis (16) . In another study, the pretreatment inflammation marker was reported to be associated with decreased survival and poor treatment response (17) . Chronic inflammatory status has been shown to be associated with an increase in regulatory T-cell numbers, changes in control point expression and dendritic cell function (18) . In view of chronic necro-inflammatory conditions and increased expression of the programmed cell death-1(PD-1) and the programmed cell death-ligand1 (PD-L1) in HCC tumor formation, immunotherapeutic agents have been involved in HCC treatment management (19) . Increased expression and upregulation of PD-1 was shown to be This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to www.erciyesmedj.com associated with the progression of HBV-associated cirrhosis to HCC and recurrence of primary tumor after surgical resection (20, 21) . Validation of PD-L1 expression and inflammatory markers may be important because they are an option as a viable test to help assess the patient's prognosis.
Our study had a few limitations, including retrospective design and the comparatively small sample size. However, regardless of these restrictions, our results had been source of the importance of inflammatory markers. The use of these simply available and non-invasive markers in combination with others could help clinicians to predict the results.
Conclusion
Few markers have been identified for predicting the survival. NMR and PNR values were first studied in patients with HCC in our study. We found that only low SIRI value was associated with increased survival in patients receiving sorafenib with HCC. Our results showed that a simple, a readily available and an inexpensive biochemical marker might be useful in refining the prognosis. However, large prospective studies should be performed to verify whether inflammatory indexes have predictive and prognostic in HCC patients. 
